Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Down 1.4% – Here’s Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO) traded down 1.4% during trading on Thursday . The company traded as low as GBX 734 and last traded at GBX 750. Approximately 9,378 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 26,501 shares. The stock had previously closed at GBX 761.

Hemogenyx Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 167.66, a quick ratio of 6.72 and a current ratio of 1.38. The stock has a market capitalization of £52.36 million, a PE ratio of -4.51 and a beta of 1.50. The company’s fifty day simple moving average is GBX 732.23 and its two-hundred day simple moving average is GBX 809.96.

Hemogenyx Pharmaceuticals (LON:HEMO) last announced its quarterly earnings results on Thursday, April 30th. The company reported GBX (170.60) earnings per share (EPS) for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.